You might think a biotech company that created a new vaccine, using novel tech like mRNA-based therapeutics, in record time to help the world fight a historic pandemic like COVID-19 would still be ...

If you think last week's decision by the federal government to halt $500 million in funding for vaccine development projects that use mRNA technology will only affect COVID vaccines, think again.

New research from the University of Pittsburgh could help scientists develop the next generation of mRNA vaccines to be more effective and less expensive to produce. A study published this week in NPJ ...

MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines—an advance that could lead to much ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase III trial that will test out a vaccine against norovirus, a frequent and ...

The outbreak has been linked to at least six confirmed infections and three deaths, according to the WHO. ・The Andes strain is one of the few hantavirus variants associated with limited ...

An mRNA therapy efficaciously corrected—in a mouse model—altered glutathione metabolism, offering a prospective avenue for treating argininosuccinic aciduria (ASA), an inherited metabolic disorder.

As the buzz builds around messenger RNA (mRNA) technology’s use for two leading COVID-19 candidates, manufacturers and regulatory professionals are facing facts: This is not simple technology. Complex ...

A pair of pessimistic third-quarter earnings calls from pharmaceutical giants Pfizer and Moderna, tracking decreased coronavirus vaccine demand and declining revenue projections, suggests biotech ...